NCT05239793Active, not recruitingEarly phase 1
Electronic Cigarette-derived Oxidants and Cardiopulmonary Effects
Translational Studies on Electronic Cigarette-derived Oxidants and Their Long-term Cardiopulmonary Effects
Source: ClinicalTrials.gov · Last updated 27 Oct 2025
Brief summary (registry, in English)
This is a pilot study on the impact of switching from cigarettes to Electronic Cigarettes (EC) on disease-related clinical symptoms and biomarkers of harm in smokers with preexisting Chronic Obstructive Pulmonary Disease (COPD). The researchers hypothesize that the smokers who switch to EC completely or significantly will experience reduced COPD symptoms, risks of exacerbations, and decreased levels of oxidative stress and inflammation.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 4 Feb 2022
- Start date
- 22 Nov 2022
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- Milton S. Hershey Medical Center
- Diseases
- COPD
- NCT number
- NCT05239793
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 30
- From 22 Nov 2022 to the primary completion date, 30 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of active, chronic drug abuse or alcohol abuse problems
- Recent history (\< 6 months) of myocardial infarction (MI)
- Any unstable or life threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or drug therapy within the past year. Antiarrhythmic drugs include amiodarone, flecainide, IV ibutilide, IV lidocaine, procainamide, propafenone, quinidine, tocainide
- Hospitalization for heart failure (NY Heart Association III or IV) within the past year
- Uncontrolled hypertension
- Known allergy to vegetable glycerin and propylene glycol
- History of seizures or medications to prevent seizures
Other
- Actively changing smoking behavior
- Unwilling or unable to provide blood samples
- Pregnant, planning to become pregnant, or nursing
- Use of tobacco products other than cigarettes in the past 30 days
Who the study is looking for
- Mild to moderate COPD
- Smokes a popular brand of cigarette
- Willing to use an e-cigarette to reduce cigarette smoking down to 75% of their daily baseline cigarette use
- Ability to read, write and understand English
- Ability to provide informed consent and attend study visits
Age in the registry: 21 years to 74 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Penn State Health Milton S. Hershey Medical Center Coordinator of this site? Confirm its status | Hershey | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.